More on NBIX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $159.00 |
|
|||
| Open | $160.01 | ||||
| 52 Wk High | $58.46 | ||||
| 52 Wk Low | $31.25 | ||||
| Day High | $161.33 | ||||
| Day Low | $156.31 | ||||
| P/E | N/A | ||||
| EPS | $-0.69 | ||||
| Volume | 2,718,236 | ||||
- Neurocrine Biosciences (NBIX) Presents New VYKAT XR (diazoxide choline) Data
- Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Foll
- Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY
- Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
- Neurocrine presents two-year CRENESSITY data showing growth improvements
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
- Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
- Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: SHERWIN STEPHEN A
- Form 4 NEUROCRINE BIOSCIENCES For: Jun 05 Filed by: Onyia Jude
Entities mentioned with nbix
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
